Autobio Diagnostics Co., Ltd. (603658.SS)

CNY 44.66

(-3.17%)

Market Cap (In CNY)

25.52 Billion

Revenue (In CNY)

4.44 Billion

Net Income (In CNY)

1.21 Billion

Avg. Volume

3.06 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
37.56-66.36
PE
-
EPS
-
Beta Value
-0.009
ISIN
CNE100002GC4
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Rui Kuan Fang
Employee Count
-
Website
https://www.autobio.com.cn
Ipo Date
2016-09-02
Details
Autobio Diagnostics Co., Ltd. engages in the research and development, production, and distribution of clinical diagnostic products. It develops immunoassay, biochemistry, microbiology, and IVD reagents; and instruments, such as automation and semi-automation systems, as well as medical laboratory solutions. The company's immunoassay products AutoLumo A2000 Plus, an automatic Chemiluminescence immunoassay analyzer; automatic microplate chemiluminescent enzyme immunoassay; and LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Its microbiology products comprise automated blood culture systems; blood culture bottles; AUTOMIC strips; and mycoplasma IES. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is based in Zhengzhou, China. Autobio Diagnostics Co., Ltd. is a subsidiary of Zhengzhou Auto Industrial Co., Ltd.